41295-51-6

Basic information

• Product Name: 4-CHLOROMETHYL-7-METHYL-CHROMEN-2-ONE
• Synonyms: 2H-1-Benzopyran-2-one,4-(chloroMethyl)-7-Methyl-;4-(Chloromethyl)-7-methyl-2H-chromen-2-one
• CAS NO: 41295-51-6
• Molecular Formula: C₁₁H₉ClO₂
• Molecular Weight: 208.65
• Mol File: 41295-51-6.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 348.3°Cat760mmHg
• Flash Point: 184.1°C
• Appearance: /
• Density: 1.273g/cm³
• Vapor Pressure: 5.1E-05mmHg at 25°C
• Refractive Index: 1.574
• CAS DataBase Reference: 4-CHLOROMETHYL-7-METHYL-CHROMEN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLOROMETHYL-7-METHYL-CHROMEN-2-ONE(41295-51-6)
• EPA Substance Registry System: 4-CHLOROMETHYL-7-METHYL-CHROMEN-2-ONE(41295-51-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 41295-51-6(Hazardous Substances Data)

Usage

General Description

4-CHLOROMETHYL-7-METHYL-CHROMEN-2-ONE is a chemical compound with the molecular formula C11H9ClO2. It is a derivative of chromen-2-one and contains a chloromethyl and a methyl group. 4-CHLOROMETHYL-7-METHYL-CHROMEN-2-ONE has potential biological activities, including anti-inflammatory and anti-cancer properties. It has been studied for its potential use in the treatment of various diseases and conditions, due to its ability to interact with specific cellular targets. Its unique structure and properties make it a valuable compound for research and potential therapeutic development.

InChI:InChI=1/C11H9ClO2/c1-7-2-3-9-8(6-12)5-11(13)14-10(9)4-7/h2-5H,6H2,1H3

Upstream product

• 638-07-3 ethyl (2-chloroaceto)acetate 
• 108-39-4 3-methyl-phenol 
• 14002-90-5 4,7-dimethyl-coumarin 
• 84097-07-4 4-Hydroxymethyl-7-methylcoumarin 
• 50402-83-0 7-methylcoumarin-4-acetic acid 
• 84096-83-3 7-methyl benzopyran-2-one-4-carboxaldehyde 

Downstream Products

• 79344-57-3 4-Anilinomethyl-7-methylcoumarin 
• 1246656-08-5 N-benzyloxycarbonyl-L-phenylalanine (7-methylcoumarin-4-yl)methyl ester 
• 845651-57-2 4-(azepan-1-ylmethyl)-7-methylchromen-2-one 
• 84097-09-6 4-Piperidinomethyl-7-methylcoumarin 

Relevant articles and documents

Synthesis of C4-substituted coumarins via Pechmann condensation catalyzed by sulfamic acid. Insights into the reaction mechanism by HRMS analysis

A series of functionalized C4-substituted coumarins were synthesized by exploring the reaction of activated and non-activated phenols and β-ketoesters under solvent-free conditions in the presence of sulfamic acid as a Br?nsted acid catalyst. Fifteen exam

Design and synthesis of pyrimidine-5-carbonitrile hybrids as COX-2 inhibitors: Anti-inflammatory activity, ulcerogenic liability, histopathological and docking studies

Two new series of 1,3,4-oxadiazole and coumarin derivatives based on pyrimidine-5-carbonitrile scaffold have been synthesized and evaluated for their COX-1/COX-2 inhibitory activity. Compounds 10c, 10e, 10h-j, 14e-f, 14i and 16 were found to be the most potent and selective inhibitors of COX-2 (IC50 0.041–0.081 μM, SI 139.74–321.95). Eight compounds were further investigated for their in vivo anti-inflammatory activity. The most active derivatives 10c, 10j and 14e displayed superior in vivo anti-inflammatory activity (% edema inhibition 39.3–48.3, 1 h; 58.4–60.5, 2 h; 70.8–83.2, 3 h; 78.9–89.5, 4 h) to the reference drug celecoxib (% edema inhibition 38.0, 1 h; 48.8, 2 h; 58.4, 3 h; 65.4, 4 h). These derivatives were also tested for their ulcerogenic liability, compound 10j showed better safety profile with reference to celecoxib while 10c and 14e exhibited mild lesions. Molecular docking studies of 10c, 10j, and 14e in the COX-2 active site revealed similar orientation and binding interactions as selective COX-2 inhibitors with a higher liability to access the selectivity side pocket.

Design, synthesis, and mechanism of dihydroartemisinin-coumarin hybrids as potential anti-neuroinflammatory agents

Cancer patients frequently suffer from cancer-related fatigue (CRF), which is a complex syndrome associated with weakness and depressed mood. Neuroinflammation is one of the major inducers of CRF. The aim of this study is to find a potential agent not only on the treatment of cancer, but also for reducing CRF level of cancer patients. In this study, total-thirty new Dihydroartemisinin-Coumarin hybrids (DCH) were designed and synthesized. The in vitro cytotoxicity against cancer cell lines (HT-29, MDA-MB-231, HCT-116, and A549) was evaluated. Simultaneously, we also tested the anti-neuroinflammatory activity of DCH. DCH could inhibit the activated microglia N9 release of NO, TNF-α, and IL-6. The docking analysis was shown that MD-2, the coreceptor of TLR4, might be one of the targets of DCH.